Internal Medicine, Rheumatology · Birmingham, AL
NPI
1689614737
Since 2006
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
2229 Cahaba Valley Dr
Birmingham, AL, 35242
Phone (205) 991-8996
Groups this clinician bills Medicare through
Medicare paid, 2024
$283K
23,934 services
Medicare patients, 2024
473
Average age 71
Drug cost, 2024
$6.6M
23,793 prescriptions
Company payments, 2025
$222K
From 21 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by David A McLain was code J0897 (injection, denosumab, 1 mg), 5,580 times for 65 patients. In total David A McLain billed 23,934 services in 30 codes, and Medicare paid $283K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-10-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 5,580 | 65 | $20.29 | $113K |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 858 | 124 | $0.73 | $625 |
| 99214 Office E&M - Established | Office | 614 | 362 | $78.37 | $48K |
| 99213 Office E&M - Established | Office | 257 | 158 | $56.73 | $15K |
| 20610 Joint Injection | Office | 211 | 118 | $48.40 | $10K |
| 96401 Chemotherapy Administration | Office | 111 | 69 | $50.26 | $5,579 |
| 96372 Injection Administration | Office | 79 | 23 | $10.47 | $827 |
| J7321 Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose | Office | 67 | 33 | $54.29 | $3,637 |
| 20600 Joint Injection | Office | 51 | 31 | $32.11 | $1,637 |
| 20605 Joint Injection | Office | 23 | 19 | $38.61 | $888 |
| 99215 Office E&M - Established | Office | 21 | 20 | $101.91 | $2,140 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 14 | 14 | $10.49 | $147 |
By year: 2022 $243K for 15,536 services; 2023 $255K for 18,727 services; 2024 $283K for 23,934 services.
Lab tests billed to Medicare, 2023
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 80305 Drug Tests | 54 | 49 | $12.35 | $667 |
| 81002 Clinical Chemistry | 18 | 18 | $3.41 | $61.38 |
Medicare prescription drug claims, 2024
In 2024, the drug David A McLain prescribed most often to Medicare patients was Hydroxychloroquine Sulfate, with 2,529 prescriptions and refills. In total David A McLain wrote 23,793 Medicare prescriptions that cost $6.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxychloroquine Sulfate Generic | 2,529 | 4,523 | 515 | $116K |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 2,063 | 2,091 | 249 | $45K |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 1,014 | 1,016 | 127 | $34K |
| Tizanidine Hcl Generic | 952 | 1,504 | 186 | $11K |
| Gabapentin Generic | 894 | 1,103 | 150 | $9,435 |
| Tramadol Hcl Generic | 718 | 742 | 129 | $4,930 |
| Prednisone Generic | 642 | 987 | 123 | $4,853 |
| Leflunomide Generic | 634 | 1,067 | 137 | $54K |
| Alprazolam Generic | 509 | 556 | 72 | $1,875 |
| Methotrexate Methotrexate Sodium | 497 | 806 | 98 | $14K |
| Clonazepam Generic | 482 | 544 | 72 | $2,822 |
| Meloxicam Generic | 460 | 799 | 106 | $2,544 |
| Zolpidem Tartrate Generic | 456 | 577 | 74 | $3,296 |
| Duloxetine Hcl Generic | 441 | 817 | 93 | $11K |
| Diclofenac Sodium Generic | 383 | 494 | 97 | $9,250 |
Brand drugs: - claims; generic drugs: 22,151 claims; opioid claims: 4,351.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid David A McLain $222K ($222K in general payments such as food, travel and fees) from 21 companies. The largest payer was Abbvie Inc. with $218K.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 47 | $218K |
| Amgen Inc. AMGN | 44 | $957 |
| Novartis Pharmaceuticals Corporation NVS | 20 | $666 |
| Mallinckrodt Hospital Products Inc. | 13 | $488 |
| GlaxoSmithKline, LLC. GSK | 13 | $392 |
| UCB, Inc. UCB.BR | 18 | $312 |
| Pfizer Inc. PFE | 15 | $276 |
| AstraZeneca Pharmaceuticals LP AZN | 9 | $276 |
| Aurinia Pharma U.S., Inc. AUPH | 2 | $259 |
| Genzyme Corporation SNY | 7 | $239 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.